01:46:58 EST Thu 26 Nov 2020
Enter Symbol
or Name

Login ID:
Mydecine Innovations Group Inc
Symbol MYCO
Shares Issued 162,762,912
Close 2020-10-16 C$ 0.29
Recent Sedar Documents

Mydecine hires Boustead to help with LSE listing

2020-10-19 08:30 ET - News Release

Mr. Josh Bartch reports


Mydecine Innovations Group Inc. has appointed United Kingdom-based Boustead Capital Markets LLP to commence the dual listing process on the London Stock Exchange for the admission of the company's common shares to the standard segment of the official list's Main Market.

Among the factors considered by the company in pursuing the dual listing, Mydecine noted that the LSE currently has a limited number of sizable psychedelics-focused biotech companies. Mydecine, as a contributing member to Drug Science UK, the only completely independent, science-led drugs charity, believes the LSE listing will provide U.K. and European investors with greater, more local exposure to a new high-quality investment choice of a business type not currently available on the exchange.


  • Mydecine's appointment of Boustead enables it to commence the LSE listing process and act on its intention for the company's common shares to trade on the Main Market in the next few months. In addition to its current listings in Canada, the United States and Germany, the company believes that a listing on the LSE makes it well positioned to bring European investors into the company's share register.
  • The LSE listing is expected to provide all investors access and exposure to:
    • European investor base in what the company believes are psychedelic-friendly countries such as the Netherlands, United Kingdom, Austria and Portugal, to name a few;
    • Support early and late-phase clinical trials;
    • Expansion of the company's telehealth platform, Mindleap Health;
    • Further development of extensive IP portfolio;
    • Furthering the development of novel types of psilocybin-based medicine and unique formulations.

Josh Bartch, chief executive officer and chairman of Mydecine Innovations Group, commented: "The board of directors has met a number of times deciding the best route and venue for the new listing of the company's securities, adding to our focus on shareholder value. We decided the LSE represented the best stock exchange for our investors, shareholders and the ongoing growth of the company. Additionally, it provides a great platform to measurably advance our investor reach within the European investor community. A LSE listing offers a number of opportunities to fast-track further potential listings to exchanges such as Nasdaq or NYSE. Mydecine Innovations Group has a global reach through the company's various planned clinical trials, research facilities, partners and scientific advisers, some of which are located directly in the U.K."

About Mydecine Innovations Group Inc.

Mydecine Innovations Group is a publicly traded life sciences syndicate, with offices in Denver, Colo., United States, and Vancouver, B.C., Canada. Mydecine is dedicated to the development and production of adaptive pathway medicine and natural health products all stemming from mushrooms. Mydecine's experienced multitalented team has the dynamic capabilities to oversee all areas of Schedule I drug development, including but not limited to synthesis, genetic research, delivery mechanism design, clinical trial execution; through to worldwide product commercialization, marketing and spore-to-sale distribution of cGMP psilocybin API's and non-psychedelic medicinal fungi. By leveraging strategic partnerships with global scientific, medical, clinical and veteran organizations; Mydecine is well positioned at the forefront of naturally derived medicine, alternative therapeutics and fungtional -- mushroom vitality consumer goods. The company's portfolio of unified companies, including Mydecine Health Sciences, Mindleap Health and NeuroPharm focus together on providing innovative and effective solutions that can help millions of people live a healthier quality life.

We seek Safe Harbor.

© 2020 Canjex Publishing Ltd. All rights reserved.